Investment Rating - The report assigns a "Buy" rating to the company [8]. Core Insights - The company has been deeply engaged in cleanroom integration for 17 years, covering three major fields: medical, laboratory, and electronics. It possesses integrated capabilities across the entire industry chain, including design, construction, procurement, and after-sales service [1][2]. - In 2024, the company is expected to achieve revenue of 1.708 billion yuan, a year-on-year increase of 6.64%, with a net profit attributable to the parent company of 67 million yuan, a decrease of 37.75%. For the first three quarters of 2025, revenue is projected to be 1.431 billion yuan, a year-on-year increase of 32.59%, with a net profit of 61 million yuan, a significant increase of 211.46% [1][2]. - The medical cleanroom business is experiencing high growth, with a rich order backlog. The company's orders in the medical and laboratory sectors have increased from 1.727 billion yuan in 2022 to 3.706 billion yuan in the first half of 2025 [1][2]. - The company has successfully entered the electronic cleanroom sector, establishing an electronic division in 2024 and winning multiple projects, with an order backlog of 121 million yuan as of the first half of 2025 [2]. Financial Summary - Revenue projections for 2025-2027 are 2.581 billion yuan, 3.535 billion yuan, and 5.051 billion yuan, representing year-on-year growth rates of 51.15%, 36.94%, and 42.89% respectively. Net profit attributable to the parent company is expected to be 137 million yuan, 215 million yuan, and 426 million yuan, with growth rates of 104.47%, 57.72%, and 97.83% respectively [2][7]. - Earnings per share (EPS) are projected to be 1.27 yuan, 2.00 yuan, and 3.95 yuan for 2025, 2026, and 2027, with corresponding price-to-earnings (PE) ratios of 24.99, 15.84, and 8.01 [2][7].